FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula I or to its pharmaceutically acceptable salt, in which L is -S(O)n-; n is 2 or 1; X is 5- or 6-element heterocyclyl attached to L via a carbon atom and optionally substituted with one or more groups independently selected from Y; R1, R2, and R3, each independently, are H or -OR11; where each R11 is independently C1-6 alkyl optionally substituted with one or more fluorine atoms; each Y is independently methyl or -C(O)CH3; where alkyl groups can be with an unbranched chain, with a branched chain or cyclic. The invention also relates to the use of a compound of the formula I and to a pharmaceutical composition based on it.
EFFECT: new compounds and a pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment of cancer mediated by inhibition of cytosolic thioredoxin reductase (TrxR1).
(I)
9 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYLSULPHONYL-SUBSTITUTED PYRIDINES AND APPLICATION THEREOF IN TREATMENT OF CANCER | 2018 |
|
RU2772935C2 |
| PYRIDINES AND USE THEREOF IN TREATING CANCER | 2016 |
|
RU2730505C2 |
| 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
| BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE | 2018 |
|
RU2780334C2 |
| BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER | 2015 |
|
RU2741914C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| JAK-INHIBITING TRIAZOLOPYRIDINE COMPOUNDS AND METHODS | 2009 |
|
RU2560153C2 |
| PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
| COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING THE COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS | 2019 |
|
RU2806857C2 |
